Streamlining Skyrizi Prior Authorization for Cardiology Patients

While Skyrizi (risankizumab) is primarily indicated for dermatologic and gastrointestinal conditions, cardiology practices frequently encounter requests for Skyrizi prior authorization for patients with complex comorbidities.

Managing prior authorizations for specialty drugs in a cardiology setting presents unique challenges, especially when dealing with medications like Skyrizi that treat co-occurring conditions. Revenue cycle directors and prior authorization coordinators require robust solutions to efficiently process these diverse requests and minimize delays in patient care.

Understanding Skyrizi (Risankizumab) and its Primary Indications

Skyrizi (risankizumab) is an IL-23 inhibitor developed by AbbVie, approved for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. Its mechanism targets the IL-23 pathway, crucial in various inflammatory and autoimmune disorders. While not a primary cardiovascular medication, patients often present with multiple health conditions requiring coordinated care, leading to its appearance in cardiology workflows.

Why Cardiology Practices Encounter Skyrizi Prior Authorizations

Cardiology practices frequently manage patients with complex medical histories, including those with inflammatory conditions like psoriasis or Crohn's disease, which may necessitate treatment with biologics like Skyrizi. Prior authorization for Skyrizi in a cardiology workflow typically arises from managing these comorbidities or for cardiac clearance prior to initiating such therapies, requiring careful coordination across specialties and often involving specialty benefit-management vendors for specific drug categories.

Documentation Requirements for Skyrizi Approval in a Comorbid Setting

Approving Skyrizi prior authorizations hinges on comprehensive documentation aligning with its FDA-approved indications. This typically includes detailed medical history, diagnosis codes for plaque psoriasis, psoriatic arthritis, or Crohn's disease, evidence of prior therapy failures, severity assessments, and relevant lab results. While the request may originate in cardiology, the clinical justification must align with the drug's primary use cases and payer-specific medical policies, potentially referencing guidelines from bodies like the American Academy of Dermatology or American College of Gastroenterology.

Common Prior Authorization Denial Reasons for Biologics in Comorbid Patients

Denials for biologics like Skyrizi, even when encountered in a cardiology setting, often stem from issues common to specialty drug PAs. These include insufficient documentation for the primary indication, lack of adherence to step-therapy protocols (e.g., failure of conventional therapies), or missing clinical criteria required by the payer or PBM. Inaccurate coding or misaligned clinical pathways can also contribute to delays, similar to denials seen for specialty cardiovascular drugs such as PCSK9 inhibitors or SGLT2 inhibitors.

Klivira's Solution for Complex Prior Authorizations in Cardiology

Klivira's platform is designed to navigate the complexities of prior authorization, including those for specialty drugs like Skyrizi within a cardiology practice. Our system automates the routing of requests to the correct payer or specialty benefit-management vendor, ensuring all necessary documentation for the drug's approved indications is collected and submitted efficiently, regardless of the originating specialty. This includes managing the specific documentation requirements for advanced cardiac imaging or interventional procedures, as well as for specialty drugs.

Integrating PA Workflows for Enhanced Patient Care

By integrating with existing EMRs using standards like SMART on FHIR, Klivira streamlines the prior authorization process, reducing manual burdens on cardiology staff. This ensures that even when a drug like Skyrizi falls outside typical cardiology-specific PAs, the necessary information—such as ejection fraction documentation for cardiac devices or LDL levels for PCSK9 inhibitors, as well as the specific criteria for Skyrizi—is accurately captured and submitted. This accelerates approvals and improves patient access to critical therapies, aligning with the efficiency needs for time-sensitive PA in cardiology.

Frequently asked questions

Why would a cardiology practice need to process Skyrizi prior authorization?

Cardiology practices often manage patients with multiple chronic conditions. A patient receiving cardiac care might also have plaque psoriasis or Crohn's disease, for which Skyrizi is indicated. The PA request for Skyrizi could originate from the cardiology clinic if they are coordinating overall patient care or providing cardiac clearance for treatment, requiring a comprehensive understanding of the patient's full medical profile.

What specific documentation is required for Skyrizi PA approval in this context?

Regardless of the requesting specialty, Skyrizi PA requires documentation supporting its FDA-approved indications: plaque psoriasis, psoriatic arthritis, or Crohn's disease. This includes diagnosis, disease severity, prior treatment failures, and relevant clinical notes, consistent with payer-specific medical policies for these conditions. The documentation must clearly demonstrate medical necessity for the drug's primary use.

How does Klivira handle prior authorizations for non-cardiology specific drugs like Skyrizi within a cardiology workflow?

Klivira's platform intelligently routes prior authorization requests based on the specific drug and payer requirements, not solely the requesting department. For Skyrizi, our system ensures the PA is directed to the appropriate PBM or payer, and aids in compiling the necessary documentation for its dermatological or gastrointestinal indications, even when initiated by a cardiology team, thereby streamlining the process.

Are there common denial reasons for Skyrizi that a cardiology practice should be aware of?

Common denial reasons for Skyrizi, even when encountered in cardiology, relate to its primary indications. These include insufficient evidence of diagnosis, failure to meet step-therapy requirements (e.g., prior use of conventional systemic therapies), or lack of documentation for disease severity, as outlined in payer medical policies. These are similar to challenges faced with other specialty drugs requiring specific clinical criteria.

Does Klivira integrate with EMRs to streamline Skyrizi prior authorizations?

Yes, Klivira integrates with major EMR systems using standards like SMART on FHIR. This integration allows for seamless extraction of patient data relevant to Skyrizi's indications, reducing manual data entry and ensuring that comprehensive clinical information is submitted for prior authorization, regardless of where the request originates in the clinic. This capability extends to all PA categories, from cardiac imaging to specialty drug approvals.